CN105688094A - Traditional Chinese medicine composition for treating depression and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating depression and preparation method thereof Download PDFInfo
- Publication number
- CN105688094A CN105688094A CN201610225362.XA CN201610225362A CN105688094A CN 105688094 A CN105688094 A CN 105688094A CN 201610225362 A CN201610225362 A CN 201610225362A CN 105688094 A CN105688094 A CN 105688094A
- Authority
- CN
- China
- Prior art keywords
- group
- chinese medicine
- medicine composition
- radix
- pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000006187 pill Substances 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 4
- 244000008991 Curcuma longa Species 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 235000003373 curcuma longa Nutrition 0.000 claims description 4
- 239000011812 mixed powder Substances 0.000 claims description 4
- 235000019640 taste Nutrition 0.000 claims description 4
- 235000013976 turmeric Nutrition 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 abstract description 7
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 6
- 206010025482 malaise Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 206010022998 Irritability Diseases 0.000 abstract 1
- 240000008058 Lilium brownii Species 0.000 abstract 1
- 235000015982 Lilium brownii Nutrition 0.000 abstract 1
- 206010033557 Palpitations Diseases 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 241000209140 Triticum Species 0.000 abstract 1
- 235000021307 Triticum Nutrition 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 19
- 230000002496 gastric effect Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 238000012449 Kunming mouse Methods 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 9
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 9
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 9
- 229960003147 reserpine Drugs 0.000 description 9
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 230000008925 spontaneous activity Effects 0.000 description 5
- 208000004130 Blepharoptosis Diseases 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 206010015995 Eyelid ptosis Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 201000003004 ptosis Diseases 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000004622 sleep time Effects 0.000 description 4
- 206010003084 Areflexia Diseases 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- -1 and therefore Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940012022 pentobarbital sodium 50 mg Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating depression and a preparation method thereof. The traditional Chinese medicine composition is prepared by radix paeoniae alba, radix bupleuri, angelica sinensis, radix curcumae, poria cocos, lilium brownii, cortex albiziae, radix glycyrrhizae, wheat, and fructus ziziphi jujubae. The traditional Chinese medicine composition has effects of soothing the liver and relieving depression and tranquilizing by nourishing the heart and is mainly applicable to fullness in the chest and hypochondrium, depression and discomfort, vexation and palpitation, irritability, insomnia and dreaminess caused by liver depression, qi stagnation and malaise. Compared with the prior art, the traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition is reasonable in prescription, high in bioavailability and free of toxic and side effects, and the clinical pharmacodynamics test effects are increased evidently.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition treating depression and preparation method thereof, belong to pharmaceutical technology field。
Background technology
Depression is caused by multiple uncertain reason, low for main clinical characteristics with notable and lasting mental state, it it is one of affective disorder mental sickness of the most easily disabling in the world, it is listed in the big mental illness of the first in the world, great misery, the serious health that have impact on people is brought to the life of people。Current doctor trained in Western medicine to the treatment of this disease mainly with the nervous system regulation medicine such as antidepressant, anxiety, all can only relief of symptoms, what have also has serious toxic and side effects。The Chinese patent medicine for the treatment of depression aspect is also a lot, but curative effect is general mostly, therefore, is developing a kind of cure rate high, the recurrence after healing can be avoided, safety, the medicine of the treatment depressive illness having no side effect, it appears very urgent。Prior art, Chinese patent publication on March 26th, 2003 discloses that (publication number is: the CN1404864A) prescription of " the Chinese medicine depression alleviating pills for the treatment of depression " and technique, the weight proportion of each herbal medicine raw material forming the described Chinese patent medicine of this invention is: Radix Paeoniae Alba 285.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 142.8g。In the time of last decade, the natural resources of Chinese medicinal materials that applicant is abundant by excavating motherland, in conjunction with substantial amounts of traditional Chinese medical science prescription theory and Study on clinical pharmacodynamics, on the basis of above prescription, groped by substantial amounts of experiment, after the consumption that being found surprisingly that increases Radix Curcumae reduces the consumption of Poria simultaneously, its clinical pharrnacokinetics experiment effect significantly improves, and without any side effects；We routinely technique be made for: pill。
Summary of the invention
It is an object of the invention to provide: a kind of Chinese medicine composition treating depression and preparation method thereof。
Chinese medicine composition of the present invention, its crude drug weight proportion is as follows:
Preparation method is: above ten tastes, takes Radix Bupleuri, Radix Angelicae Sinensis, the Radix Paeoniae Alba, turmeric powder are broken into mixed powder, then by Poria, Bulbus Lilii, Cortex Albiziae, Radix Glycyrrhizae, Semen Tritici aestivi, Fructus Jujubae boiling 2 times, add water 12 times amount for the first time, decocts 1.5 hours, pours out medicinal liquid standby, add water 10 times amount for the second time, decoct 1 hour, merge twice decocting liquid, filter, concentration, record the extractum that relative density is 1.30-1.35 when 60 DEG C, make the watered pill with the mixing of four Chinese medicine powder, dry and make 1000g pill。
Prior art, Chinese patent publication on March 26th, 2003 discloses that (publication number is: the CN1404864A) prescription of " the Chinese medicine depression alleviating pills for the treatment of depression " and technique, the weight proportion of each herbal medicine raw material forming the described Chinese patent medicine of this invention is: Radix Paeoniae Alba 285.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 142.8g。In the time of last decade, the natural resources of Chinese medicinal materials that applicant is abundant by excavating motherland, in conjunction with substantial amounts of traditional Chinese medical science prescription theory and Study on clinical pharmacodynamics, on the basis of above prescription, groped by substantial amounts of experiment, after the consumption that being found surprisingly that increases Radix Curcumae reduces the consumption of Poria simultaneously, its clinical pharrnacokinetics experiment effect significantly improves, and without any side effects；We routinely technique be made for: pill。
Pharmacodynamic test of active extract proves: traditional Chinese medicinal composition raw materials weight proportion " Radix Paeoniae Alba 285.7g of the present invention, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 171.4g, Poria 142.8g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 142.8g " with screening weight proportion 1: " Radix Paeoniae Alba 265.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 162.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 75.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 152.8g " and screening weight proportion 2: " Radix Paeoniae Alba 255.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 172.8g " and former invention weight proportion: " Radix Paeoniae Alba 285.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 142.8g " to compare, results of pharmacodynamic test is significantly increased。
Pharmacodynamic test of active extract
One, medicine:
1, raw material:
A, pill group of the present invention: prepared by Radix Paeoniae Alba 285.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 171.4g, Poria 142.8g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 142.8g。
B, screen 1 group: prepared by Radix Paeoniae Alba 265.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 162.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 75.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 152.8g。
C, screen 2 groups: prepared by Radix Paeoniae Alba 255.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 172.8g。
D, former invention group (according to publication number being: in the description of CN1404864A prepared by detailed description of the invention): prepared by Radix Paeoniae Alba 285.7g, Radix Bupleuri 214.3g, Radix Angelicae Sinensis 142.8g, Radix Curcumae 142.8g, Poria 171.4g, Bulbus Lilii 171.4g, Cortex Albiziae 171.4g, Radix Glycyrrhizae 85.7g, Semen Tritici aestivi 214.3g, Fructus Jujubae 142.8g。
2, the method for making of a, b, c, d is:
Above ten tastes, take Radix Bupleuri, Radix Angelicae Sinensis, the Radix Paeoniae Alba, turmeric powder are broken into mixed powder, then by Poria, Bulbus Lilii, Cortex Albiziae, Radix Glycyrrhizae, Semen Tritici aestivi, Fructus Jujubae boiling 2 times, add water 12 times amount for the first time, decocts 1.5 hours, pours out medicinal liquid standby, add water 10 times amount for the second time, decoct 1 hour, merge twice decocting liquid, filter, concentration, record the extractum that relative density is 1.30-1.35 when 60 DEG C, make the watered pill with the mixing of four Chinese medicine powder, dry and make 1000g pill。
Two: process of the test and result of the test
Experiment purpose: by pharmacological experiment studies such as pill group of the present invention, b group, c group and the calmness of d group pill, hypnosis, analgesia, adjustment body temperature, antidepressants, pill group of the present invention, b group, c group and d group being contrasted, observes the power of its pharmacological action。
Test method: pill group of the present invention, b group, c group and the impact on spontaneous activity in mice of the d group；Impact on mice time for falling asleep；Impact on mouse sleep time；Impact on mice Radiant heat pain stimulus；Impact on depression model mouse temperature；Reserpine induction depression model mice is tested。
One, the impact on spontaneous activity in mice
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g。
2, medicine: pill group of the present invention, b group, c group, four dosage groups of d group。Medicine configures with distilled water on pretreatment, gastric infusion。
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18～22g, it is randomly divided into 5 groups, often group 10。The distilled water of matched group gavage same volume；Pill group of the present invention, b group, c group, d group be gastric infusion 6.8g crude drug/kg respectively。Successive administration 5d, after last administration 1h, puts into mice photoelectric counter, measures mice 5min activity number of times。Experimental result: in Table 1
The table 1 impact on spontaneous activity in mice
* * P < 0.01 compared with matched group；* P < 0.05；With pill group of the present invention than △ P < 0.05。
Result shows: pill group of the present invention, b group, c group and d group can significantly reduce the Assay of spontaneous activity of mice, and pill group of the present invention has the difference (P < 0.01) of pole significance with d group compared with matched group；B group has significant difference (P < 0.05) with c group compared with matched group；B group, c group, d group have significant difference (P < 0.05) compared with pill group of the present invention。Visible, pill group of the present invention than b group, c group, d group sedation strong。
Two, the impact on mice time for falling asleep
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g。
2, medicine: pill group of the present invention, b group, c group, four dosage groups of d group。Medicine configures with distilled water on pretreatment, gastric infusion。
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18～22g, it is randomly divided into 5 groups, often group 10。The distilled water of matched group gavage same volume；Pill group of the present invention, b group, c group, d group be gastric infusion 6.8g crude drug/kg respectively。Successive administration 5d, every day 1 time, 1h lumbar injection pentobarbital sodium 50mg/kg after last administration, with mice righting reflex loss for time for falling asleep, record time for falling asleep。Experimental result: in Table 2
The table 2 impact on mice time for falling asleep
* * P < 0.01 compared with matched group；* P < 0.05；With pill group of the present invention than △ P < 0.05。
Result shows: pill group of the present invention, b group, c group and d group substantially shorten time for falling asleep, and pill group of the present invention has the difference (P < 0.01) of pole significance with d group compared with matched group；B group has significant difference (P < 0.05) with c group compared with matched group；B group, c group, d group have significant difference (P < 0.05) compared with pill group of the present invention。Visible, pill group of the present invention than b group, c group, d group syngignoscism strong。
Three, the impact on mouse sleep time
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g。
2, medicine: pill group of the present invention, b group, c group, four dosage groups of d group。Medicine configures with distilled water on pretreatment, gastric infusion。
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18～22g, it is randomly divided into 5 groups, often group 10。The normal saline of matched group gavage same volume；Pill group of the present invention, b group, c group, d group be gastric infusion 6.8g crude drug/kg respectively。Successive administration 5d, after last administration 1h, lumbar injection pentobarbital sodium 40mg/kg, the length of one's sleep (with righting reflex loss for time for falling asleep, be sleep time from righting reflex loss to recovery time) of record mice。Experimental result: in Table 3
The table 3 impact on mouse sleep time
* * P < 0.01 compared with matched group；* P < 0.05；With pill group of the present invention than △ P < 0.05。
Result shows: pill group of the present invention, b group, c group and d group can be obviously prolonged the length of one's sleep of mice, and pill group of the present invention has the difference (P < 0.01) of pole significance with d group compared with matched group；B group has significant difference (P < 0.05) with c group compared with matched group；B group, c group, d group have significant difference (P < 0.05) compared with pill group of the present invention。Visible, pill group of the present invention is stronger than the effect that b group, c group, the improvement of d group are slept。
Four, the impact on mice Radiant heat pain stimulus
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g。
2, medicine: pill group of the present invention, b group, c group, four dosage groups of d group。Medicine configures with distilled water on pretreatment, gastric infusion。
Experimental technique
Being fixed on by mice in Mus cylinder, a light beam planoconvex lens is irradiated in rat-tail after focusing on, lower 1/3 intersection, measures and starts the time that light source to rat-tail swings rapidly, i.e. TFL, also known as the threshold of pain。First measuring the Basic Pain Threshold value before mice administration, Basic Pain Threshold value is rejected less than 3s or the irritation more than 10s or blunt animal。Mice after screening 50, male and female half and half, it is randomly divided into 5 groups, often group 10。The distilled water of matched group gavage same volume；Pill group of the present invention, b group, c group, d group be gastric infusion 6.8g crude drug/kg respectively。Successive administration 5d, every day 1 time, after last administration 1h, carries out radiant heat stimulation by mice。After record administration 1h, there is the time that whipping reacts, be the pain threshold after medication。Experimental result: in Table 4
The table 4 impact on mice Radiant heat pain stimulus
* * P < 0.01 compared with matched group；* P < 0.05；With pill group of the present invention than △ P < 0.05。
Result shows: pill group of the present invention, b group, c group and d group are remarkably improved the pain threshold of Radiant heat pain stimulus mice, and pill group of the present invention has the difference (P < 0.01) of pole significance with d group compared with matched group；B group has significant difference (P < 0.05) with c group compared with matched group；B group, c group, d group have significant difference (P < 0.05) compared with pill group of the present invention。Visible, pill group of the present invention than b group, c group, d group analgesic activity strong。
Five, the impact on depression model mouse temperature
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g。
2, medicine: pill group of the present invention, b group, c group, four dosage groups of d group。Medicine configures with distilled water on pretreatment, gastric infusion。
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18～22g, it is randomly divided into 5 groups, often group 10。The distilled water of matched group gavage same volume；Pill group of the present invention, b group, c group, d group be gastric infusion 6.8g crude drug/kg respectively。Successive administration 5d, every day 1 time, is administered pre-test mice anus temperature in 5d, and after last administration 1h, lumbar injection reserpine 2.5mg/kg, after drug administration by injection, 3h surveys mice anus temperature, record anus temperature change again。Experimental result: in Table 5
The table 5 impact on depression model mouse temperature
* * P < 0.01 compared with matched group；* P < 0.05；With pill group of the present invention than △ P < 0.05。
Result shows: pill group of the present invention, b group, c group and d group can recover rapidly the body temperature that reserpine induced mice declines, and pill group of the present invention has the difference (P < 0.01) of pole significance with d group compared with matched group；B group has significant difference (P < 0.05) with c group compared with matched group；B group, c group, d group have significant difference (P < 0.05) compared with pill group of the present invention。Visible, pill group of the present invention than b group, c group, d group regulate body temperature effect strong。
Six, reserpine induction depression model mice experiment
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18～22g。
2, medicine: pill group of the present invention, b group, c group, four dosage groups of d group。Medicine configures with distilled water on pretreatment, gastric infusion。
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18～22g, it is randomly divided into 5 groups, often group 10。The distilled water of matched group gavage same volume；Pill group of the present invention, b group, c group, d group be gastric infusion 6.8g crude drug/kg respectively。Successive administration 5d, every day 1 time, after last administration 1h, holds up mice after lumbar injection reserpine 2.5mg/kg, 1h。Marking according to blepharoptosis degree, it is 1 point that eye closes 1/4, and it is 2 points that eye closes 1/2, and it is 3 points that eye closes 3/4, and fully closed is 4 points。Calculate blepharoptosis degree antagonistic rate。Experimental result: in Table 6
Table 6 reserpine induction depression model mice is tested
* * P < 0.01 compared with matched group；* P < 0.05；With pill group of the present invention than △ P < 0.05。
Result shows: pill group of the present invention, b group, c group and d group can substantially suppress the sag of eyelid after mouse peritoneal injection reserpine, improving blepharoptosis degree antagonistic rate, pill group of the present invention has the difference (P < 0.01) of pole significance with d group compared with matched group；B group has significant difference (P < 0.05) with c group compared with matched group；B group, c group, d group have significant difference (P < 0.05) compared with pill group of the present invention。Visible, pill group of the present invention than b group, c group, d group antidepressant effect strong。
Experimental result: pill group of the present invention, b group, c group and d group can significantly reduce the Assay of spontaneous activity of mice；Substantially shorten time for falling asleep；The length of one's sleep of mice can be obviously prolonged；It is remarkably improved the pain threshold of Radiant heat pain stimulus mice；The body temperature that reserpine induced mice declines can be recovered rapidly；Can substantially suppress the sag of eyelid after mouse peritoneal injection reserpine, improve blepharoptosis degree antagonistic rate。
Conclusion: pill group of the present invention is stronger than pharmacological actions such as b group, c group, the calmness of d group, hypnosis, analgesia, adjustment body temperature, antidepressants, and therefore, pill group of the present invention is than b group, c group, d group dispersing the stagnated live-QI to relieve the stagnation of QI, and the function of tranquilizing by nourishing the heart is strong。
1, the preparation of pill of the present invention:
Prescription:
Preparation method:
Above ten tastes, take Radix Bupleuri, Radix Angelicae Sinensis, the Radix Paeoniae Alba, turmeric powder are broken into mixed powder, then by Poria, Bulbus Lilii, Cortex Albiziae, Radix Glycyrrhizae, Semen Tritici aestivi, Fructus Jujubae boiling 2 times, add water 12 times amount for the first time, decocts 1.5 hours, pours out medicinal liquid standby, add water 10 times amount for the second time, decoct 1 hour, merge twice decocting liquid, filter, concentration, record the extractum that relative density is 1.30-1.35 when 60 DEG C, make the watered pill with the mixing of four Chinese medicine powder, dry and make 1000g pill。
Claims (2)
1. the Chinese medicine composition treating depression, it is characterised in that the crude drug weight proportion of described Chinese medicine composition is:
2. the preparation method of Chinese medicine composition according to claim 1, it is characterised in that:
Above ten tastes, take Radix Bupleuri, Radix Angelicae Sinensis, the Radix Paeoniae Alba, turmeric powder are broken into mixed powder, then by Poria, Bulbus Lilii, Cortex Albiziae, Radix Glycyrrhizae, Semen Tritici aestivi, Fructus Jujubae boiling 2 times, add water 12 times amount for the first time, decocts 1.5 hours, pours out medicinal liquid standby, add water 10 times amount for the second time, decoct 1 hour, merge twice decocting liquid, filter, concentration, record the extractum that relative density is 1.30-1.35 when 60 DEG C, make the watered pill with the mixing of four Chinese medicine powder, dry and make 1000g pill。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610225362.XA CN105688094A (en) | 2016-04-12 | 2016-04-12 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610225362.XA CN105688094A (en) | 2016-04-12 | 2016-04-12 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105688094A true CN105688094A (en) | 2016-06-22 |
Family
ID=56218618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610225362.XA Pending CN105688094A (en) | 2016-04-12 | 2016-04-12 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105688094A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107158336A (en) * | 2017-05-09 | 2017-09-15 | 赵新 | A kind of medicine pill for treating dry tired type depressive illness |
| CN108403724A (en) * | 2018-04-20 | 2018-08-17 | 北京斯利安药业有限公司 | A kind of composition and preparation method thereof of adjustable mood |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1404864A (en) * | 2002-10-27 | 2003-03-26 | 郑州豫密药业股份有限公司 | Chinese medicine for treatment of depression |
-
2016
- 2016-04-12 CN CN201610225362.XA patent/CN105688094A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1404864A (en) * | 2002-10-27 | 2003-03-26 | 郑州豫密药业股份有限公司 | Chinese medicine for treatment of depression |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107158336A (en) * | 2017-05-09 | 2017-09-15 | 赵新 | A kind of medicine pill for treating dry tired type depressive illness |
| CN108403724A (en) * | 2018-04-20 | 2018-08-17 | 北京斯利安药业有限公司 | A kind of composition and preparation method thereof of adjustable mood |
| CN108403724B (en) * | 2018-04-20 | 2020-11-20 | 北京斯利安药业有限公司 | Composition capable of regulating emotion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102973685B (en) | Anti-fatigue traditional Chinese medicine preparation and preparation method thereof | |
| CN104161982A (en) | Traditional Chinese medicine composition for treating sleep disorder | |
| CN103127472B (en) | Traditional Chinese medicine compound for refractory insomnia | |
| CN105311219A (en) | Health Jieyu Ningshen mixture | |
| CN104274725A (en) | Traditional Chinese medicinal composition for treating depression and insomnia as well as preparation method and application thereof | |
| CN101966298B (en) | Traditional Chinese medicine for treating wind-cold numbness | |
| CN105688094A (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN101366903B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN103845694A (en) | Traditional Chinese medicine for treating hypoglycemia | |
| CN103520646B (en) | Chinese medicine composition for treating depression and preparation method of Chinese medicine composition | |
| CN105456582A (en) | Traditional Chinese medicine for treating depressive disorder and anxiety disorder | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN103690780A (en) | Heart-invigorating and sedative pill and preparation method thereof | |
| CN101129633A (en) | Medicine for neurasthenia and its preparation | |
| CN105477302A (en) | Insomnia treating traditional Chinese medicine composition and preparation method thereof | |
| CN105853907A (en) | Traditional Chinese medicinal composition and preparation method of depression resolving pills | |
| CN105535849A (en) | Traditional Chinese medicine for treating liver depression insomnia | |
| CN103638376A (en) | Traditional Chinese medicine tablet for treating rosacea | |
| CN102631429A (en) | Medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
| CN103393782A (en) | Traditional Chinese medicine composition with function of resolving stagnation for tranquilization, preparation and preparation method thereof | |
| CN103393961B (en) | Traditional Chinese medicine for treating cervical spondylosis and preparation method thereof | |
| CN105456817A (en) | Traditional Chinese medicine preparation for treating depression and anxiety | |
| CN104288643A (en) | Pharmaceutical composition for treating consumptive disease nocturnal emission and preparation method thereof | |
| CN104324212A (en) | Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof | |
| CN105362999A (en) | Traditional Chinese medicine preparation for preventing and treating infantile repeated cold and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160622 |
|
| WD01 | Invention patent application deemed withdrawn after publication |